ORPHA:96264
49,XXXXY syndrome
Publications
104
43.2th percentile
Trials
0
Interventional, condition-specific
Researchers
459
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
The 49,XXXXY syndrome represents a chromosomal anomaly of the aneuploidic type characterized by the presence of three extra X chromosomes in males.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019929
- UMLS:C0265499
- NCIT:C185635
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
104 matched papers (35 in last 10 years) Source
- Phenotype characterisedPresent
64 HPO annotations (e.g. Joint hypermobility; Hypogonadism; Carious teeth) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
64
Associated phenotypes · MONDO:0019929
- Joint hypermobility
- Hypogonadism
- Carious teeth
- Abnormal dental enamel morphology
- Global developmental delay
Showing 5 of 64 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
104
104 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
104 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
35 in the last 10 years · high confidence · 43.2th percentile (publications denominator)
Phrase hits: 104 · MeSH hits: 0
Who's working on it?
459
Distinct author names in 104 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Sadeghin T7 papers · 2021
Research Department, The Focus Foundation, Davidsonville, Maryland.
Papers in Europe PMC - 02Samango-Sprouse CA6 papers · 2021
George Washington University of the Health Sciences, Washington, DC, USA. cssprouse@aol.com
Papers in Europe PMC - 03Gropman AL5 papers · 2021
Department of Neurology, Children's National Medical Center, Washington, District of Columbia 20010, USA. agropman@cnmc.org
Papers in Europe PMC - 04Lasutschinkow PC5 papers · 2021
Research Department, The Focus Foundation, Davidsonville, Maryland.
Papers in Europe PMC - 05Porter GF4 papers · 2021
Research Department, The Focus Foundation, Davidsonville, Maryland.
Papers in Europe PMC - 06Gropman A3 papers · 2021
Department of Neurology, George Washington University, Washington, DC, USA.
Papers in Europe PMC - 07Powell S3 papers · 2021
Department of Economics, George Washington University, Washington, District of Columbia, USA.
Papers in Europe PMC - 08Samango-Sprouse C3 papers · 2025
Department of Research, The Focus Foundation, Davidsonville, MD, USA. cssprouse@email.gwu.edu.
Papers in Europe PMC - 09Blumenthal JD2 papers · 2014
Child Psychiatry Branch, National Institute of Mental Health, Bethesda 20892-1600, MD, USA.
Papers in Europe PMC - 10Borghgraef M2 papers · 1990
Department of Human Biology U.Z. Gasthuisberg, Leuven, Belgium.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 60 · after dedupe 58 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 58 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (58)
- ctis·2025-524027-49-00·Authorised·An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)
skipped — LLM skipped (--skip-llm)
- ctis·2024-517799-40-00·Authorised·A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial - GOIRC-04-2024
skipped — LLM skipped (--skip-llm)
- ctis·2026-525830-49-00·Authorised·A Phase 1 Randomized, Double-Blind, placebo-controlled, clinical study to evaluate safety and Pharmacokinetics, of Single Ascending Doses and Multiple Ascending Doses of AIK3a305 in Healthy Volunteers
skipped — LLM skipped (--skip-llm)
- ctis·2025-523479-49-00·Authorised, recruiting·A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis
skipped — LLM skipped (--skip-llm)
- ctis·2022-502365-26-00·Authorised·A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
skipped — LLM skipped (--skip-llm)
- ctis·2025-522957-20-00·Authorised, ongoing·A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1
skipped — LLM skipped (--skip-llm)
- ctis·2025-524759-29-00·Authorised·COLOMBE - A multicentre, single arm, phase 1/2 study, aiming to assess the safety and efficacy of nivolumab and imiquimod combination in vulvar squamous cell carcinoma patients
skipped — LLM skipped (--skip-llm)
- ctis·2024-516253-49-01·Authorised, recruiting·HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanced HER2-positive breast cancer
skipped — LLM skipped (--skip-llm)
- ctis·2024-519081-49-00·Authorised, ongoing·A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis
skipped — LLM skipped (--skip-llm)
- ctis·2025-520538-49-00·Authorised·ACUMEN: Phase I Dose Escalation and Cohort Expansion study to affirm the safety of pharmacological doses of a novel formulation of intravenous melatonin in babies with hypoxic-ischaemic encephalopathy (HIE) to augment therapeutic hypothermia (HT) treatment; to reduce the incidence and severity of disability in babies with moderate-severe HIE.
skipped — LLM skipped (--skip-llm)
- ctis·2024-520317-49-02·Authorised·Intraperitoneal treatment with fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating factor in patients with multi-quadrant peritonitis undergoing abdominal surgery: A randomized placebo-controlled trial (TRIPLE)
skipped — LLM skipped (--skip-llm)
- ctis·2024-512511-49-00·Authorised·SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immuno-chemotherapy in patients with early triple-negative breast cancer (TNBC). An open-label randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK
skipped — LLM skipped (--skip-llm)
- ctis·2024-517883-49-00·Authorised, ongoing·The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
skipped — LLM skipped (--skip-llm)
- ctis·2024-516367-80-00·Authorised, ongoing·Prospective randomized Phase II trial on Induction Immunochemotherapy followed by surgery or definitive chemoradiation and consolidation Durvalumab (MEDI4736) in resectable and borderline resectable stage IIIA/B NSCLC
skipped — LLM skipped (--skip-llm)
- ctis·2024-516510-38-00·Authorised, ongoing·Mesenchymal stromal cells for traumatic brain injury. A multicenter, double blind, randomized, placebo-controlled phase II trial
skipped — LLM skipped (--skip-llm)
- ctis·2024-517396-20-00·Authorised·Phase 1 (sequential)/2a (parallel), double-blind, multicenter, randomized, controlled study to evaluate the safety and immunogenicity of two administrations of OVX033 sarbecovirus candidate vaccine, given intramuscularly (IM) at one-month interval, at three dose levels, in comparison to placebo, in subjects aged 18 years and older
skipped — LLM skipped (--skip-llm)
- ctis·2025-520487-18-00·Expired·Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple-negative breast cancer (TNBC) patients: TONIC-trial
skipped — LLM skipped (--skip-llm)
- ctis·2024-517864-49-01·Authorised, ongoing·Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi- centre, 2 parallel arms randomized controlled trial
skipped — LLM skipped (--skip-llm)
- ctis·2024-518004-49-00·Authorised, ongoing·Oxytocin and attachment development: Looking beyond the expected?
skipped — LLM skipped (--skip-llm)
- ctis·2024-519066-49-01·Authorised, ongoing·Electrochemotherapy versus standard radiotherapy for the treatment of basal cell carcinoma
skipped — LLM skipped (--skip-llm)
- ctis·2024-518301-18-00·Authorised, ongoing·Phase 1 trial of trametinib and gilteritinib for the treatment of relapsed or refractory acute leukemia patients
skipped — LLM skipped (--skip-llm)
- ctis·2024-517946-32-00·Authorised, ongoing·A 12-month follow up study of probiotic supplementation effects in subjects with autoimmune uveitis.
skipped — LLM skipped (--skip-llm)
- ctis·2024-517804-12-00·Authorised, ongoing·Sacubitril/Valsartan in PriMAry preventIoN of the cardiotoxicity of systematic breaST canceR trEAtMent. Randomized, multicenter, double-blind, placebo-controlled study.
skipped — LLM skipped (--skip-llm)
- ctis·2024-516106-31-00·Expired·STAR-TREC: Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer?
skipped — LLM skipped (--skip-llm)
- ctis·2024-515323-11-00·Expired·Prevention of cardiac Dysfunction during Adjuvant breast cancer therapy: A Randomized, Placebo-controlled, Multicenter Trial (PRADA-II)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for 49,XXXXY syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"49,XXXXY syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"49,XXXXY syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T05:00:40.647Z